Condition
Refractory Shock
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 3 (1)
P 4 (1)
Trial Status
Unknown3
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04339868Phase 2Unknown
Terlipressin for Refractory Septic Shock
NCT04323709Completed
Levosimendan for Veno-arterial ECMO Weaning
NCT04110418Phase 2Unknown
Methylene Blue Versus Vasopressin Analogue for Treatment of Septic Shock in Preterm Neonate
NCT03038503Phase 3Unknown
What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin
NCT03120637Phase 4Completed
Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue
Showing all 5 trials